China’s NMPA suspends Abraxane imports after U.S. inspection

China’s suspension of the importation and sale of Celgene’s Abraxane by BeiGene following an inspection at a U.S. manufacturing site demonstrates how far the country has come in its drive to ensure safety of drugs, even those sourced from overseas.

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), one of China’s most prominent biotechs, told BioCentury that the suspension blocks BeiGene from providing Abraxane nab-paclitaxel using its current stock of the drug. The pharma expects a supply disruption, which could reduce BeiGene’s market share three months after winning its bid under China’s nationwide centralized procurement program for generic and off-patent drugs...